Click Project Title to learn more at the AoW site.
Who is conducting the study?
Richard Junghans, MD, PhD, Associate Professor of Medicine, Boston University School of Medicine, and Roger Williams Medical Center, Providence, Rhode Island
Description from the Army of Women site
The purpose of this Phase Ib clinical trial is to determine whether a high dose of designer T cells is better when given with or without interleukin 2 (IL2), a drug that is thought to stimulate the immune system. For this reason, some of the study participants will receive modified T cells alone, whereas others will receive modified T cells along with IL2. The researcher would like to enroll about 12 people in this study.
Phase I studies typically look at the safety and side effects of a new treatment. This is a Phase Ib study, so it is not only monitoring safety but also looking at whether the experimental treatment being studied is effective. In this case, the effectiveness will be measured by how active the T cells become and how much the tumor shrinks.
Whether you have metastatic breast cancer or not, please share this post by tweeting or e-mailing this post. The Internet helps us easily share messages with others, so please take advantage of this great medium.
5 6 7 8
© 2004–2010 Donna Peach. All rights reserved.